Spots Global Cancer Trial Database for fibroblast growth factor receptor (fgfr) inhibitor
Every month we try and update this database with for fibroblast growth factor receptor (fgfr) inhibitor cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) | NCT03822117 | Solid Tumor Mal... | Pemigatinib | 18 Years - | Incyte Corporation | |
Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205) | NCT04003610 | Metastatic Urot... Unresectable Ur... | Pemigatinib Pembrolizumab Gemcitabine Carboplatin | 18 Years - | Incyte Corporation | |
Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) | NCT03822117 | Solid Tumor Mal... | Pemigatinib | 18 Years - | Incyte Corporation |